美国血液技术公司宣布,其Vascade MVP® XL静脉血管闭合系统已获得美国食品药品监督管理局的扩大标签使用批准。这一监管里程碑意味着该创新器械的应用范围将进一步拓展,为更多患者提供微创手术后的血管闭合解决方案。
此次标签扩展彰显了公司在血管闭合技术领域的持续创新能力,也为临床医生提供了更灵活的手术工具选择。该系统采用独特的闭合机制,能够有效提升手术效率并降低并发症风险。
美国血液技术公司宣布,其Vascade MVP® XL静脉血管闭合系统已获得美国食品药品监督管理局的扩大标签使用批准。这一监管里程碑意味着该创新器械的应用范围将进一步拓展,为更多患者提供微创手术后的血管闭合解决方案。
此次标签扩展彰显了公司在血管闭合技术领域的持续创新能力,也为临床医生提供了更灵活的手术工具选择。该系统采用独特的闭合机制,能够有效提升手术效率并降低并发症风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.